| Literature DB >> 35372133 |
Lingai Pan1,2, Fengsheng Wu3, Qingqing Cai3, Zhuofei Xu3, Huan Hu2, Tian Tang2, Ruiming Yue2, Yifu Hou4, Xiaoqin Zhang2, Yuan Fang3, Xiaobo Huang2, Yan Kang1.
Abstract
Solid organ transplantation (SOT) is the final therapeutic option for recipients with end-stage organ failure, and its long-term success is limited by infections and chronic allograft dysfunction. Viral infection in SOT recipients is considered an important factor affecting prognosis. In this study, we retrospectively analyzed 43 cases of respiratory infections in SOT recipients using metagenomic next-generation sequencing (mNGS) for bronchoalveolar lavage fluid (BALF). At least one virus was detected in 26 (60.5%) recipients, while 17 (39.5%) were virus-negative. Among virus-positive recipients, cytomegalovirus (CMV) was detected in 14 (32.6%), Torque teno virus (TTV) was detected in 9 (20.9%), and other viruses were detected in 6 (14.0%). Prognostic analysis showed that the mortality of the virus-positive group was higher than that of the virus-negative group regardless whether it is the main cause of infection. Analysis of different types of viruses showed that the mortality of the CMV-positive group was significantly higher than that of the CMV-negative group, but no significant difference was observed in other type of virus groups. The diversity analysis of the lung microbiome showed that there was a significant difference between the virus-positive group and the negative group, in particular, the significant differences in microorganisms such as Pneumocystis jirovecii (PJP) and Moraxella osloensiswere detected. Moreover, in the presence of CMV, Pneumocystis jirovecii, Veillonella parvula, and other species showed dramatic changes in the lung of SOT patients, implying that high degree of co-infection between CMV and Pneumocystis jirovecii may occur. Taken together, our study shows that the presence of virus is associated with worse prognosis and dramatically altered lung microbiota in SOT recipients.Entities:
Keywords: cytomegalovirus; lung microbiome; mortality; solid organ transplant; virus
Mesh:
Year: 2022 PMID: 35372133 PMCID: PMC8967177 DOI: 10.3389/fcimb.2022.863399
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 6.073
Figure 1Study design in solid organ transplantation.
Demographic and Clinical Characteristics of the 43 Recipients with solid organ transplantation.
| Characteristic | Value |
|---|---|
| Mean age, y | 52 |
| Male | 31 |
| BMI, kg/m2 | 20.8 |
|
| |
| Mean SOFA | 6.7 |
| Mean APACHE II | 10.9 |
|
| |
| HBV | 4 (9.3) |
| HBV and HTN | 3 (7.0) |
| HBV, HTN and DM | 1 (2.3) |
| HTN | 12 (27.9) |
| HTN and COPD | 1 (2.3) |
| TB | 1 (2.3) |
| TB and CHD | 1 (2.3) |
| Chronic bronchitis | 1 (2.3) |
| DM | 1 (2.3) |
| Uremia | 1 (2.3) |
| Non | 17 (39.5) |
|
| |
| Kidney* | 26 |
| Lung | 13 |
| Liver^ | 4 |
|
| |
| Mean ICU length of stay, days | 8.8 |
BMI, Body Mass Index; SOFA, Sequential Organ Failure Score; APACHE II, Acute Physiology and Chronic Health Score II; HBV, Hepatitis B Virus; HTN, Hypertension; DM, Diabetes mellitus; COPD, Chronic obstructive pulmonary disease; CHD, Coronary heart disease.
*1 recipient underwent a second renal transplant. ^1 recipient underwent a second liver transplant. BALF of the two recipients were collected after the first transplant with lung infection.
Figure 2Diversity and reads counts of viruses identified in this study. CMV, Human betaherpesvirus 5; TTV, Torque teno virus; HSV1, Human alphaherpesvirus 1; EBV, Human gammaherpesvirus 4; BKV, BK virus; B19, Human erythroparvovirus 19; HHV-7, Human betaherpesvirus 7; VZV, Varicella Zoster Virus. The numbers on the histogram represent the sample sizes of the corresponding virus. The numbers in the table represent the reads of mNGS results. S14 and S7 etc, sample number. The samples are sorted according to hierarchical clustering with Euclidean distance.
Demographic and Clinical Characteristics of study cohort.
| Severity of illness | Virus | Non-virus | P-value |
|---|---|---|---|
| Mean SOFA | 6.8 | 6.5 | 0.77 |
| Mean APACHE II | 10.7 | 11.1 | 0.53 |
|
| |||
| Good | 19 (73.1%) | 16 (94.1%) | 0.083 |
| Poor | 7 (26.9%) | 1 (5.9%) | |
|
|
|
|
|
| Mean SOFA | 6.6 | 6.7 | 0.98 |
| Mean APACHE II | 11.6 | 10.6 | 0.52 |
|
| |||
| Good | 9 (64.3%) | 26 (89.7%) | 0.046 |
| Poor | 5 (35.7%) | 3 (10.3%) |
Good=survival; Poor=died.
Figure 390-Days Survival proportions of different virus. (A) Survival proportions of virus and non-virus, p = 0.0828; (B) survival proportions of CMV and non-CMV, p = 0.0456; (C) survival proportions of TTV and non-TTV, p = 0.7306. Recipient number is displayed in the Number at risk.
Figure 4Differences of lung microbiota in groups. (A) Top 20 most abundant species and their relative abundance in virus and non-virus recipients; (B) there were significant differences in top-20 species (such as Pneumocystis jirovecii, Moraxella osloensis, CMV) and other non-top species between virus and non-virus group; (C) top 20 most abundant species and their relative abundance in CMV and non-CMV infectious recipients; (D) there were significant differences in top-20 species (such as Pneumocystis jirovecii, Veillonella parvula) and other non-top species between CMV and non-CMV group.